- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Patient presents with unilateral blurred vision
A 50-year-old Haitian-born woman preÂsented to the Bascom Palmer Eye Institute with a complaint of suddenly decreased vision in her right eye over the previous 4 days. The patient denied other symptoms of pain, redness, photophobia, floaters, or photopsias.
The patient worked as a nursing assistant at an assisted living facility. She had been unable to work due to recent problems with vision and general weakness. She had noted a 40-pound weight loss over the previous 2 months. The patient denied a history of substance use but had been taking myriad herbal medications.
Examination
Case unfolding
Once the findings of hemorrhage were explained, the patient volunteered a past diagnosis of chronic myelogenous leukemia (CML), which was diagnosed 5 years previously at another hospital. At the time of diagnosis, the patient was treated with imatinib (Gleevec, Novartis) therapy, which was continued for 3 years. There was no history of radiation treatment. The patient had been unable to take imatinib for the past 2 years due to financial reasons and had been following with a "natural doctor," who had been treating her with herbal supplements, including vitamin C, a liquid preparation (Floradix, Flora), goldenseal, and black elderberry extract (Sambucol, Healthcare Brands).
